Find similar products:
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
The text only version may be available in large print, Braille or audio CD.
For further information call emc accessibility on
0800 198 5000.
The product code(s) for this leaflet is: PLGB 05293/0182.
Adtralza 150 mg solution for injection in pre-filled syringe
Adtralza® 150 mg solution for injection in pre-filled syringe
tralokinumab
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
1. What Adtralza® is and what it is used for
2. What you need to know before you use Adtralza®
3. How to use Adtralza®
4. Possible side effects
5. How to store Adtralza®
6. Contents of the pack and other information
Adtralza contains the active substance tralokinumab.
Tralokinumab is a monoclonal antibody (a type of protein) that blocks the action of a protein called IL-13. IL-13 plays a major role in causing the symptoms of atopic dermatitis.
Adtralza is used to treat adult and adolescent patients 12 years and older with moderate-to-severe atopic dermatitis, also known as atopic eczema. Adtralza may be used with eczema medicines that you apply to the skin or it may be used on its own.
Using Adtralza for atopic dermatitis can improve your eczema and reduce the related itching and skin pain.
If you think you may be allergic, or you are not sure, ask your doctor, pharmacist or nurse for advice before using Adtralza.
Talk to your doctor, pharmacist or nurse before using Adtralza.
Allergic reactions
Very rarely, medicines can cause allergic (hypersensitivity) reactions and severe allergic reactions called anaphylaxis. You must look out for signs of these reactions (such as breathing problems, swelling of the face, mouth, and tongue, fainting, dizziness, feeling lightheaded (because of low blood pressure), hives, itching and skin rash) while you are using Adtralza.
Stop using Adtralza and tell your doctor or get medical help immediately if you notice any signs of an allergic reaction. Such signs are listed in the beginning of section 4.
Parasitic infection in the intestines
Adtralza may reduce your resistance to infections caused by parasites. Any parasitic infection should be treated before you start treatment with Adtralza. Tell your doctor if you have diarrhoea, gas, upset stomach, greasy stools, and dehydration which could be signs of a parasitic infection. If you live in a region where these infections are common or if you are travelling to such a region, tell your doctor.
Eye problems
Talk to your doctor if you have any new or worsening eye problems, including eye pain or changes in vision.
Do not give this medicine to children below the age of 12 years because the safety and benefits of Adtralza are not yet known in this population.
Tell your doctor or pharmacist
If you are pregnant or breast-feeding, think you may be pregnant or you are planning to have a baby, ask your doctor for advice before using this medicine. The effects of Adtralza in pregnant women are not known; therefore, it is preferable to avoid using it during pregnancy unless your doctor advises you to use it.
If applicable, you and your doctor should decide if you will breast-feed or use Adtralza. You should not do both.
Adtralza is unlikely to reduce your ability to drive and use machines.
This medicine contains less than 1 mmol sodium (23 mg) per 150 mg that is to say essentially “sodium-free”.
Always use this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure.
Each pre-filled syringe contains 150 mg of tralokinumab.
Adtralza is given by injection under your skin (subcutaneous injection). You and your doctor or nurse can decide if you can inject Adtralza yourself.
Inject Adtralza yourself only after you have been trained by your doctor or nurse. A caregiver may also give you your Adtralza injection after proper training.
Do not shake the syringe.
Read the “Instructions for Use” before injecting Adtralza.
If you use more of this medicine than you should or the dose has been given too early, talk to your doctor, pharmacist or nurse.
If you miss injecting a dose at the right time, inject Adtralza as soon as possible. Then the next dose should be injected at the regular scheduled time.
Do not stop using Adtralza without speaking to your doctor first.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Adtralza can cause serious side effects, including allergic (hypersensitivity) reactions such as anaphylaxis; the signs may include:
Stop using Adtralza and tell your doctor or get medical help immediately if you notice any signs of allergic reaction.
Other side effects
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.
Keep in the original package in order to protect from light.
Store in a refrigerator (2 °C to 8 °C). Do not freeze.
If necessary, Adtralza may be kept at room temperature up to 30 °C in the original package for a maximum of 14 days. Do not store above 30 °C. Throw away Adtralza if it is not used within 14 days of storage at room temperature.
If you need to permanently remove the carton from the refrigerator, write down the date of removal on the carton, and use Adtralza within 14 days. Adtralza must not be refrigerated again during this period.
Do not use this medicine if you notice that it is cloudy, discoloured or has particles in it.
Do not throw away any medicines via wastewater or household waste. Ask your doctor, pharmacist or nurse how to throw away medicines you no longer use. These measures will help protect the environment.
Adtralza is a clear to opalescent, colourless to pale yellow solution, supplied in a glass pre-filled syringe with a needle guard.
Adtralza is available in unit packs containing 2 pre-filled syringes or in multipacks containing 4 (2 packs of 2) or 12 (6 packs of 2) pre-filled syringes.
Not all pack sizes may be marketed.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in June 2025
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
The Instructions for Use with information about on how to inject Adtralza is shown on the other side of this leaflet.
For information in large print, Braille or audio/CD, telephone +44 (0)1844 347333.
Adtralza
tralokinumab
Solution for injection in pre-filled syringe
Read these instructions before you start using Adtralza pre-filled syringes and each time you get a new package. There may be new information. You should also talk to your healthcare professional about your medical condition or your treatment.
Keep this Instructions for Use so you can read it again if necessary.
Each pre-filled syringe contains 150 mg of tralokinumab.
The Adtralza pre-filled syringes are for single-use only.
Important information you need to know before injecting Adtralza:
1a: Gather the supplies needed for your injection
For each Adtralza dose you will need:
1b: Take the Adtralza pre-filled syringe carton out of the refrigerator
Do not use the Adtralza pre-filled syringes if the syringes have been stored at room temperature for more than 14 days.
1c: Let the Adtralza pre-filled syringes reach room temperature
Place the Adtralza carton on the flat surface and wait 30 minutes before you inject Adtralza to let the pre-filled syringes reach room temperature (20 ºC to 30 ºC). This will help to make injection of Adtralza more comfortable.
1d: Remove the Adtralza pre-filled syringes from the carton
Remove the 2 Adtralza pre-filled syringes one by one from the carton by grasping the body (not the plunger rod) of the Adtralza pre-filled syringes.
1e: Inspect the 2 Adtralza pre-filled syringes
If you cannot use the syringes, dispose of them in a puncture-resistant container and use new syringes.
2a: Choose the area for your injections
2b: Wash your hands and prepare your skin
3a: Pull off the Adtralza needle cover
Hold the Adtralza pre-filled syringe body with one hand, pull the needle cover straight off with your other hand and throw it into the puncture-resistant container.
3b: Insert the needle
With one hand, gently pinch and hold a fold of skin where you cleaned the injection area. With the other hand, insert the needle completely into your skin at a 45-90 degree angle.
3c: Inject the medicine
Use your thumb to firmly push the plunger head all the way down. All the medicine is injected when you cannot push the plunger head any further.
3d: Release and remove
Lift your thumb off the plunger head. The needle will automatically move back inside the syringe body and lock into place.
Throw away the used Adtralza pre-filled syringe in a puncture-resistant container. See Step 5 “Disposing of Adtralza”.
To get your full prescribed dose, you will need to give a second injection. Get a new Adtralza pre-filled syringe and repeat Steps 3 and 5.
Note
Make sure you give your second injection in the same body area, but at least 3 cm away from the first one.